After 18 years of development, Biovest International plans to file applications for marketing approval for its personalized therapeutic cancer vaccine BiovaxID by the end of 2012 in Canada, the EU and the US.
After 18 years of development, Biovest International plans to file applications for marketing approval for its personalized therapeutic cancer vaccine BiovaxID by the end of 2012 in Canada, the EU and the US.
Tampa, Florida-based Biovest has been meeting with regulatory officials to make sure it has the clinical data necessary to win...
Create an account to read this article
Already a subscriber?
The biotech announced positive results in the PIK3CA wild-type population in second-line HR+/HER2- breast cancer for its PAM inhibitor.
With a US approval any time soon now looking unlikely, analysts are revising Blenrep’s peak sales guidance downwards.
The privately held German pharma firm is hoping to bring a new generation of pulmonary fibrosis and cancer drugs to market but their commercial success is not yet a certainty.
With $216m in initial funding, the newly launched company is aiming to develop a cell therapy-based universal immuno-oncology option for solid tumor indications.
With a US approval any time soon now looking unlikely, analysts are revising Blenrep’s peak sales guidance downwards.
The privately held German pharma firm is hoping to bring a new generation of pulmonary fibrosis and cancer drugs to market but their commercial success is not yet a certainty.
Just days after Roche stopped shipments of the DMD gene therapy following safety concerns raised by two patient deaths, its EU approval application has hit a block.
